153 related articles for article (PubMed ID: 16181843)
1. Cost effectiveness of chest computed tomography after lung cancer resection: a decision analysis model.
Kent MS; Korn P; Port JL; Lee PC; Altorki NK; Korst RJ
Ann Thorac Surg; 2005 Oct; 80(4):1215-22; discussion 1222-3. PubMed ID: 16181843
[TBL] [Abstract][Full Text] [Related]
2. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
[TBL] [Abstract][Full Text] [Related]
3. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance.
Lou F; Huang J; Sima CS; Dycoco J; Rusch V; Bach PB
J Thorac Cardiovasc Surg; 2013 Jan; 145(1):75-81; discussion 81-2. PubMed ID: 23127371
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of surveillance computed tomography in detecting recurrent or new primary lung cancer in patients with completely resected lung cancer.
Korst RJ; Kansler AL; Port JL; Lee PC; Altorki NK
Ann Thorac Surg; 2006 Sep; 82(3):1009-15; discussion 1015. PubMed ID: 16928526
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer.
Schreyögg J; Weller J; Stargardt T; Herrmann K; Bluemel C; Dechow T; Glatting G; Krause BJ; Mottaghy F; Reske SN; Buck AK
J Nucl Med; 2010 Nov; 51(11):1668-75. PubMed ID: 21051648
[TBL] [Abstract][Full Text] [Related]
7. Surveillance computed tomography after complete resection for non-small cell lung cancer: results and costs.
Korst RJ; Gold HT; Kent MS; Port JL; Lee PC; Altorki NK
J Thorac Cardiovasc Surg; 2005 Mar; 129(3):652-60. PubMed ID: 15746751
[TBL] [Abstract][Full Text] [Related]
8. Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis.
Das P; Ng AK; Earle CC; Mauch PM; Kuntz KM
Ann Oncol; 2006 May; 17(5):785-93. PubMed ID: 16500905
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec.
Nguyen VH; Peloquin S; Lacasse Y
Can Respir J; 2005; 12(1):19-25. PubMed ID: 15776130
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.
Guadagnolo BA; Punglia RS; Kuntz KM; Mauch PM; Ng AK
J Clin Oncol; 2006 Sep; 24(25):4116-22. PubMed ID: 16943528
[TBL] [Abstract][Full Text] [Related]
11. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan.
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Chest; 2000 Feb; 117(2):346-53. PubMed ID: 10669673
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of whole-body CT screening.
Beinfeld MT; Wittenberg E; Gazelle GS
Radiology; 2005 Feb; 234(2):415-22. PubMed ID: 15670999
[TBL] [Abstract][Full Text] [Related]
13. Low-dose chest computed tomography for lung cancer screening among Hodgkin lymphoma survivors: a cost-effectiveness analysis.
Wattson DA; Hunink MG; DiPiro PJ; Das P; Hodgson DC; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):344-53. PubMed ID: 25104066
[TBL] [Abstract][Full Text] [Related]
14. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis.
Puri V; Crabtree TD; Kymes S; Gregory M; Bell J; Bradley JD; Robinson C; Patterson GA; Kreisel D; Krupnick AS; Meyers BF
J Thorac Cardiovasc Surg; 2012 Feb; 143(2):428-36. PubMed ID: 22169443
[TBL] [Abstract][Full Text] [Related]
15. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
[TBL] [Abstract][Full Text] [Related]
16. The risk of second primary tumors after resection of stage I nonsmall cell lung cancer.
Rice D; Kim HW; Sabichi A; Lippman S; Lee JJ; Williams B; Vaporciyan A; Smythe WR; Swisher S; Walsh G; Putnam JB; Hong WK; Roth J
Ann Thorac Surg; 2003 Oct; 76(4):1001-7; discussion 1007-8. PubMed ID: 14529975
[TBL] [Abstract][Full Text] [Related]
17. Endoscopic ultrasound-guided fine-needle aspiration in patients with non-small cell lung cancer and prior negative mediastinoscopy.
Eloubeidi MA; Tamhane A; Chen VK; Cerfolio RJ
Ann Thorac Surg; 2005 Oct; 80(4):1231-9. PubMed ID: 16181845
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective.
Alzahouri K; Lejeune C; Woronoff-Lemsi MC; Arveux P; Guillemin F
Clin Radiol; 2005 Apr; 60(4):479-92. PubMed ID: 15767106
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography-computed tomography for postoperative surveillance in non-small cell lung cancer.
Choi SH; Kim YT; Kim SK; Kang KW; Goo JM; Kang CH; Kim JH
Ann Thorac Surg; 2011 Nov; 92(5):1826-32; discussion 1832. PubMed ID: 22051278
[TBL] [Abstract][Full Text] [Related]
20. Imaging surveillance and survival for surgically resected non-small-cell lung cancer.
Backhus LM; Farjah F; Liang CK; He H; Varghese TK; Au DH; Flum DR; Zeliadt SB
J Surg Res; 2016 Jan; 200(1):171-6. PubMed ID: 26231974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
